Račić Anđelka, Krstonošić Veljko, Micov Ana, Pecikoza Uroš, Dobričić Vladimir, Turković Erna, Krajišnik Danina
Department of Pharmacy, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina.
Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia.
Pharmaceutics. 2025 Apr 15;17(4):517. doi: 10.3390/pharmaceutics17040517.
The incorporation of polymers into drug delivery vehicles has been shown to be an effective strategy to prolong the residence time of active ingredients in the precorneal tear film and to increase ocular bioavailability. The aim of this study was to develop novel, viscous eye drops containing olopatadine (OCH) as the active ingredient, polysaccharides hydroxypropyl guar gum (HPG), and sodium hyaluronate (SH), individually, and in combination as functional polymers. Viscous eye drops containing 0.1% OCH in combination with HPG (0.25%) and SH (0.4%), were prepared and evaluated for their physicochemical properties, rheological behavior, mucoadhesion, and preliminary stability. A novel rheological method was used to evaluate the resistance of the eye drops under simulated blinking conditions. In vivo efficacy was evaluated using an ocular itch test in mice to compare the formulations with a commercial product. The formulations remained stable and transparent, with physicochemical parameters within acceptable ranges. Rheological studies confirmed pseudoplastic flow, with the HPG-SH combination exhibiting enhanced viscosity and shear-thinning properties for prolonged retention in the eye. Mucoadhesion was highest in SH-HPG formulations. During simulated blinking cycles, eye drops containing a combination of SH and HPG polymers fully regained their initial viscosity during the resting periods. Preliminary stability studies indicate that the formulated eye drops exhibit satisfactory physicochemical stability under various storage conditions. In vivo, OCH-SH and OCH-HPG-SH drops provided prolonged antipruritic and analgesic effects compared to the reference product. Polysaccharide-based innovative formulations improve OCH retention, enhancing therapeutic efficacy and patient compliance in the treatment of allergic conjunctivitis.
将聚合物纳入药物递送载体已被证明是一种有效的策略,可延长活性成分在角膜前泪膜中的停留时间并提高眼部生物利用度。本研究的目的是开发新型粘性滴眼液,其分别含有奥洛他定(OCH)作为活性成分、多糖羟丙基瓜尔胶(HPG)和透明质酸钠(SH),并将它们组合作为功能性聚合物。制备了含有0.1% OCH与HPG(0.25%)和SH(0.4%)组合的粘性滴眼液,并对其理化性质、流变行为、粘膜粘附性和初步稳定性进行了评估。采用一种新型流变学方法来评估滴眼液在模拟眨眼条件下的抗性。使用小鼠眼部瘙痒试验评估体内疗效,以将这些制剂与市售产品进行比较。这些制剂保持稳定且透明,理化参数在可接受范围内。流变学研究证实为假塑性流动,HPG-SH组合表现出增强的粘度和剪切变稀特性,以便在眼中延长保留时间。SH-HPG制剂的粘膜粘附性最高。在模拟眨眼周期中,含有SH和HPG聚合物组合的滴眼液在静止期完全恢复其初始粘度。初步稳定性研究表明,所配制的滴眼液在各种储存条件下均表现出令人满意的理化稳定性。在体内,与参比产品相比,OCH-SH和OCH-HPG-SH滴眼液提供了更长时间的止痒和镇痛作用。基于多糖的创新制剂改善了OCH的保留,提高了过敏性结膜炎治疗中的治疗效果和患者依从性。